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Mitochondrial protein sorting as a therapeutic
target for ATP synthase disorders
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Marc Blondel5, Jean-Paul di Rago3,4, Martin van der Laan2,6 & Lars M. Steinmetz1,8,10
Mitochondrial diseases are systemic, prevalent and often fatal; yet treatments remain scarce.
Identifying molecular intervention points that can be therapeutically targeted remains a major
challenge, which we confronted via a screening assay we developed. Using yeast models of
mitochondrial ATP synthase disorders, we screened a drug repurposing library, and applied
genomic and biochemical techniques to identify pathways of interest. Here we demonstrate
that modulating the sorting of nuclear-encoded proteins into mitochondria, mediated by the
TIM23 complex, proves therapeutic in both yeast and patient-derived cells exhibiting
ATP synthase deficiency. Targeting TIM23-dependent protein sorting improves an array
of phenotypes associated with ATP synthase disorders, including biogenesis and activity
of the oxidative phosphorylation machinery. Our study establishes mitochondrial protein
sorting as an intervention point for ATP synthase disorders, and because of the central role
of this pathway in mitochondrial biogenesis, it holds broad value for the treatment of mito-
chondrial diseases.
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M
itochondrial dysfunction has been implicated in a host
of diseases with a wide range of symptoms and
molecular phenotypes, which present significant chal-
lenges to diagnosis, let alone treatment1–4. Many of these
disorders affect mitochondrial ATP synthase, which produces
most of the cellular ATP required in humans through the process
of oxidative phosphorylation (OXPHOS). Defects in the structure
or assembly of this crucial enzyme result in severe diseases that
manifest primarily in children, often shortly after birth. Various
ATP synthase disorders resulting from defects in the structure or
assembly of this enzyme complex have been described, including
neuropathy, ataxia and retinitis pigmentosa (NARP), a fatal
encephalopathy known as Leigh syndrome, and hypertrophic
cardiomyopathy5–7. Many of the molecular consequences of these
disorders, ranging from deficient ATP production to widespread
effects on mitochondrial biogenesis, structure and metabolism
have been studied using yeast models, due to the extensive
conservation of mitochondrial functions and the ability to
manipulate the yeast mitochondrial and nuclear genomes7.
One relevant model of ATP synthase disorders is a strain
lacking Fmc1 (fmc1D), a factor required for the assembly of the F1
sector of ATP synthase at high temperatures8. Loss of Fmc1
directly and severely impairs ATP synthase assembly, while
secondarily impairing the respiratory chain biogenesis and
activity as well as mitochondrial membrane potential9. These
secondary consequences on the respiratory chain are frequently
observed in the context of reduced ATP synthase activity10–13,
and are believed to reflect a regulatory mechanism that maintains
a balanced production of ATP synthase and respiratory chain
complexes7,12,14. Because of these deficiencies, fmc1D yeast
display impaired growth on non-fermentable carbon sources
like glycerol. Their drastic reduction in fully assembled ATP
synthase along with their impaired mitochondrial respiration
result in 90% less mitochondrial ATP synthesis8,9. Since these
phenotypes are also found in multiple patients15,16, we have
leveraged this model system to develop a stringent, high-
throughput screening assay for the identification of compounds
that suppress ATP synthase deficiency14.
In this study, we apply our screening assay to search for
pathways that can be therapeutically targeted for the treatment of
ATP synthase disorders. By following up one of the hits using
chemical–genomic analysis, we identify the major mitochondrial
protein sorting pathway mediated by the inner membrane
presequence translocase (TIM23 complex) as a potential inter-
vention point for these disorders. We show that a specific
modulation of this pathway, which we recapitulate using a genetic
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Figure 1 | Identification of NaPT in a drug screen and a potential new therapeutic target revealed by a genomic screen. (a) NaPT rescues respiratory
growth of the fmc1D mutant, a yeast model for ATP synthase disorders, in a dose-dependent manner. fmc1D cells were spread onto solid rich glycerol
medium, indicated amounts of NaPT were spotted onto filters, and plates were incubated at 36 C for 6 days. High concentrations of NaPT are toxic, as
indicated by the regions with no growth immediately surrounding the filters. The halos of growth at dose-dependent distances from the filters correspond
to the lower therapeutic concentrations. DMSO ( ), compound vehicle. (b) NaPT treatment improves survival of atp6-T8993G (JCP239) cybrids
derived from ATP synthase disorder patients in glucose-deprived medium in a dose-dependent manner. Data from three replicates per condition are
indicated by points; height of the bar represents the mean. Statistical significance: *Po0.05, (Wilcoxon’s test) relative to the untreated sample (0). DHLA,
positive control, drug currently in clinical trials for mitochondrial encephalopathies14,18. (c) The chemical–genomic profile of NaPT identifies mitochondrial
protein sorting as a potential target. On treatment of the yeast genome-wide deletion collection with 8.35 mM NaPT, TIM17 and TIM23, essential
genes involved in mitochondrial protein import, displayed pronounced deletion sensitivity/haploinsufficiency (calculated relative to the same strain
collection treated with DMSO as a negative control; see Methods). Increasing data density is depicted as lighter shades of blue. (d) TIM17-deletion
sensitivity is specific to NaPT. Frequency distribution of the TIM17þ / mutant z-scores (see Methods) from 726 published chemical–genomic profiles23
across 332 compounds compared with the score obtained for NaPT.
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modification, is sufficient to rescue several phenotypes associated
with ATP synthase deficiency. Notably, modulating this pathway
is also effective in cells derived from ATP synthase-disorder
patients, demonstrating the conservation of these therapeutic
effects. Our study thus provides the first indication that
mitochondrial protein sorting is a promising therapeutic target
for the treatment of ATP synthase disorders.
Results and discussion
Sodium pyrithione improves growth of ATP synthase-deficient
cells. From a drug repurposing library17, our screening assay
identified sodium pyrithione (NaPT), a small molecule currently
used as an antiseptic. NaPT markedly improved the respiratory
growth of fmc1D yeast in a dose-dependent manner (Fig. 1a).
Notably, this compound was also effective in a cybrid (cytoplasmic
hybrid) cell line derived from NARP patients carrying the atp6-
T8993G mutation, a mutation also implicated in maternally
inherited Leigh’s syndrome7,18. This mutation severely perturbs
OXPHOS in both patient tissues and cells derived from them,
resulting in extremely poor survival of the latter in glucose-
deprived medium18–20. Treatment with NaPT improved the
survival of atp6-T8993G cybrids, in a dose-dependent manner,
up to 1.8-fold, but did not affect control cybrids (Fig. 1b;
Supplementary Fig. 1a; Supplementary Data Set 1). These data
suggest that NaPT rescues ATP synthase deficiency via a pathway
that is conserved between yeast and humans.
Chemical-genomic profiling of NaPT-treated cells. To identify
the pathway(s) through which NaPT could be rescuing ATP syn-
thase deficiencies, we carried out systematic chemical–genomic
profiling using the yeast genome-wide deletion collection (Fig. 1c;
Supplementary Data Set 2). In this approach, pronounced sensitivity
of heterozygous deletion mutants (that is, haploinsufficiency) to
inhibitory concentrations of a chemical indicates the genes and
pathways involved in the chemical’s mechanism of action21–23. The
10 deletion mutants most sensitive to inhibitory concentrations of
NaPT implicated two essential mitochondrial pathways: protein
sorting and iron-sulfur cluster biogenesis. The latter is consistent
with a previous report that the zinc salt of PT inhibits yeast growth
through copper influx and inactivation of iron-sulfur cluster
proteins24. The mitochondrial protein sorting pathway was
indicated by the genes TIM17 and TIM23, which encode core
components of the highly conserved presequence translocase of the
inner mitochondrial membrane (TIM23 complex)25,26. The
sensitivities of the TIM17þ / and TIM23þ / mutants to NaPT
were far greater than their sensitivity to hundreds of previously
profiled compounds23 (Fig. 1d; Supplementary Fig. 1b), indicating
that the chemical-genetic interaction between NaPT and the TIM23
machinery is specific.
The TIM23 complex mediates the sorting of nuclear-encoded
mitochondrial proteins with amino terminal presequences as
targeting signals to either the inner mitochondrial membrane or
the matrix, which includes many subunits of ATP synthase and
respiratory chain complexes27–29. Notably, a recent study has
demonstrated that the import of respiratory chain proteins into
mitochondria via TIM23 can be directly coupled to their
assembly into active complexes30. As outlined above, the
activity of these respiratory chain complexes is often perturbed
in ATP synthase disorders12,13,15,16. Taken together, these
observations suggested that the sorting of presequence-carrying
proteins into mitochondria could be an attractive therapeutic
target for ATP synthase deficiencies.
NaPT modulates mitochondrial protein sorting via TIM23.
The expression levels of subunits of the TIM23 complex and the
presequence-translocase-associated import motor, which is
essential for matrix translocation27–29, were not affected by NaPT
treatment in wild-type or fmc1D cells (Supplementary Fig. 1c).
Therefore, to directly test the effect of NaPT on both
mitochondrial protein import activities mediated by TIM23, we
carried out in vitro import assays using established model
substrates targeted to the inner membrane (cytochrome b2-
DHFR) or the matrix (cytochrome b2D-DHFR, lacking the
membrane-sorting signal)31,32 (Fig. 2a,b; Supplementary Fig. 6;
Supplementary Data Set 3). In the presence of NaPT, import of
matrix-targeted cytochrome b2D-DHFR was significantly
inhibited (33% slower, Po5.5 10 13, Fig. 2a). In contrast,
import of inner membrane-targeted cytochrome b2-DHFR was
enhanced (46% faster, Po1.3 10 8; Fig. 2b). When importing
a saturating amount of cytochrome b2D-DHFR (using
recombinantly expressed purified protein versus the in vitro-
synthesized substrate above, see Methods), the impairment of
matrix import by NaPT and its dose dependence were striking
(Fig. 2c; Supplementary Fig. 6). We verified that NaPT does not
disrupt general properties required for mitochondrial protein
import, including membrane integrity and inner membrane
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Figure 2 | NaPT selectively and differentially modulates mitochondrial
protein sorting via the presequence translocase TIM23. (a) Import of
in vitro-synthesized, radiolabelled cytochrome b2D-DHFR, a model protein
targeted to the mitochondrial matrix, into isolated yeast mitochondria
(p¼ precursor; i¼ intermediate) in the presence or absence of 100mM
NaPT. The lower panel displays quantifications of the bands detected by
autoradiography in three independent experiments (imported, protease-
resistant i-form). The signal obtained in the presence DMSO after the
longest incubation time was set to 100%. Error bars represent the s.e.m.
Dc, mitochondrial inner membrane potential. (b) Import of in vitro
synthesized, radiolabelled cytochrome b2-DHFR, targeted to the inner
membrane, into isolated mitochondria (m¼mature). The lower panel
displays quantifications of the bands (imported, protease-resistant m-form)
as in a. (c) Importing saturating amounts of recombinantly expressed and
purified cytochrome b2D-DHFR causes a pronounced, concentration-
dependent inhibition by NaPT. Import reactions were analysed by
immunoblotting using an antibody against DHFR.
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potential (Dc) (Supplementary Fig. 2a,b). Moreover, other major
mitochondrial protein import pathways, including the assembly
of b-barrel proteins into the outer membrane by the SAM (TOB)
complex and insertion of proteins with internal import signals
into the inner membrane by the TIM22 complex27,28, were not
affected by NaPT (Supplementary Fig. 2c,d). We conclude that
NaPT does not interfere with the general import competence of
mitochondria, but selectively and differentially modulates import
of presequence proteins via the TIM23 pathway. These findings
are in line with recent studies indicating that the downregulation
of mitochondrial protein import via TIM23 can be employed as a
stress-responsive mechanism to maintain protein homeostasis in
mitochondria33,34.
To our knowledge, this is the first report of a compound with
highly specific effects on TIM23-mediated protein sorting, a
central pathway of mitochondrial biogenesis. Nevertheless, we
also found that some effects of NaPT on protein sorting in vitro
were influenced by the presence of copper (Supplementary
Figs. 3,7c–e), which is consistent with previous reports24 and
could complicate both the drug’s in vivo effects35 and its viability
as a drug development candidate. We therefore sought an
independent approach to confirm the role of TIM23-mediated
mitochondrial protein sorting in suppressing ATP synthase
deficiencies.
Increased Tim21 levels rescue ATP synthase-deficient cells. To
study the therapeutic potential of modulating mitochondrial
protein sorting in isolation, we applied a genetic modification that
recapitulates the effects of NaPT on the TIM23 pathway. Over-
expression of Tim21, a regulatory subunit of the TIM23 complex,
shifts the activity state of TIM23 from matrix translocation
towards inner membrane insertion31,32, which we confirmed in
fmc1D mitochondria (Fig. 3a,b; wild-type import results,
confirmation of Tim21 overexpression and steady-state levels of
other mitochondrial proteins in Supplementary Figs 4a–c and
6d,e). We found that Tim21 overexpression caused a substantial
restoration of respiratory growth of the fmc1D mutant,
while wild-type yeast was unaffected (Fig. 3c; Supplementary
Fig. 4d). Likewise in human, overexpression of TIMM21 led to a
significant increase in the survival of atp6-T8993G NARP patient-
derived cybrids (2.4-fold, Po0.05, Fig. 3d; Supplementary Data
Set 1; confirmation of TIMM21 overexpression in Supplementary
Fig. 1d), while wild-type cybrids were unaffected (Supplementary
Fig. 1e). These observations support TIM23’s involvement in
mutant rescue and attest to an evolutionarily conserved
therapeutic effect of modulating mitochondrial protein sorting
on ATP synthase dysfunction.
Tim21 promotes OXPHOS biogenesis in a yeast disease model.
Another evolutionary parallel between yeast and human Tim21 is
their interaction with OXPHOS complexes: the former physically
couples respiratory chain supercomplexes to the TIM23
machinery36, and the latter facilitates the assembly of nuclear-
encoded subunits into cytochrome c oxidase (complex IV)30.
Notably, perturbations in complex IV biogenesis have been
observed in ATP synthase disorders10,12. Moreover, we observed
that Tim21 overexpression reduced the accumulation of matrix-
localized aggregates composed of unassembled ATP synthase
subunits in fmc1D mitochondria (Supplementary Fig. 4e).
Altogether, these findings led us to investigate whether Tim21
could be facilitating the assembly of imported proteins into
mature OXPHOS complexes in yeast. We indeed discovered
pronounced improvements in OXPHOS complex assembly
specific to our disease model (Fig. 4a,b; import controls in
Supplementary Figs 5g and 8f,g). Our results demonstrate that
Tim21 can promote the biogenesis of deficient OXPHOS
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Figure 3 | Genetic modulation of mitochondrial protein sorting rescues yeast and human ATP synthase disorder models. (a,b) Tim21 overexpression
induces NaPT-like modulation of TIM23-mediated mitochondrial protein import. Assays as in Fig. 2a,b were performed with mitochondria isolated
from fmc1D cells carrying Tim21 overexpression (Tim21m) versus empty plasmids. Data are representative of three independent experiments. (c) Tim21
overexpression suppresses the respiratory growth defect of fmc1D yeast. Strains were grown in liquid rich glycerol media (YPG) at 36 C until
stationary phase; their maximum growth rate (in generations per day, see Methods) is displayed in a boxplot (WT (wild type), n¼ 3; fmc1D, n¼ 5).
(d) Overexpression of TIMM21, the human ortholog of yeast TIM21, improves cybrid survival. NARP atp6-T8993G cybrids were transduced with lentiviral
particles carrying TIMM21 and GFP or RFP alone as a negative control. After 6 days, surviving cells were counted using flow cytometry. Individual replicates
are displayed as points; height of the bar represents the mean; * indicates statistical significance (Po0.05, Wilcoxon’s test).
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complexes, and indicate that the connection between mito-
chondrial protein import and complex assembly could be an
important target for alleviating mitochondrial dysfunction.
Tim21 enhances ATP synthesis in disease model mitochondria.
Finally, we investigated the impact of modulating TIM23-depen-
dent mitochondrial protein sorting on the defective bioenergetic
properties of fmc1D mitochondria that are also found in other
mutants with deficient ATP synthase8–12. An improvement in
respiratory chain activity in response to Tim21 overexpression was
revealed by marked increases in both mitochondrial inner mem-
brane potential (Dc) and mitochondrial respiration (maximal
uncoupled rates in whole cells and isolated mitochondria;
Fig. 4c,d; Supplementary Fig. 5i; Supplementary Data Set 4).
Consistent with the improvement in OXPHOS complex assembly,
the specific activities of cytochrome c oxidase and ATP synthase
were also significantly enhanced (Fig. 4d; latter as oligomycin-
sensitive ATP hydrolysis, corroborated by in-gel ATPase activity
in Supplementary Fig. 5f; Supplementary Data Set 4). These
activity increases were reflected in the elevated steady-state levels
of OXPHOS complexes (Supplementary Figs 5a–e and 8a–e).
Most importantly, mitochondrial ATP synthesis was increased by
greater than twofold (Fig. 4d). None of these bioenergetic
properties were affected by Tim21 overexpression in wild-type
yeast (Supplementary Fig. 5j; Supplementary Data Set 4). Taken
together, our findings demonstrate that modulation of
mitochondrial protein sorting via the TIM23 pathway alleviates
not only a primary ATP synthase deficiency, but also an array of
critical downstream phenotypes found in these disorders10,12,15,16.
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Figure 4 | Modulation of mitochondrial protein sorting considerably restores the bioenergetic capacity of a yeast model of ATP synthase disorders.
(a,b) Tim21 overexpression accelerates the incorporation of subunits Qcr8 and Su h into cytochrome bc1-containing respiratory chain supercomplexes and
ATP synthase, respectively, in fmc1D mitochondria. Radiolabelled, in vitro-synthesized proteins were imported into isolated mitochondria and their assembly
into their respective complexes (indicated with arrows) was followed using BN-PAGE and autoradiography. Dc, mitochondrial inner membrane potential;
III2/IV2, III2/IV1, III2: respiratory chain supercomplexes formed by complex III (cytochrome bc1) and IV (cytochrome c oxidase, COX); V1 and V2, monomeric
and dimeric F1Fo-ATP synthase (complex V), respectively. (c) Genetic modulation of mitochondrial protein sorting improves the mitochondrial inner
membrane potential (Dc) of fmc1D yeast. The Dc of indicated mitochondria was monitored using a DiSC3(5) fluorescence quenching assay (see Methods).
The difference in fluorescence before and after addition of valinomycin indicates the magnitude of Dc of the analysed mitochondria. (d) Genetic
modulation of mitochondrial protein sorting improves the bioenergetic capacity of fmc1D yeast. The following parameters were measured in isolated
mitochondria: maximal/uncoupled respiratory rate (upper left), maximal/uncoupled cytochrome c oxidase (COX) activity with ascorbate/TMPD as a
substrate (upper right), oligomycin-sensitive ATP hydrolysis using a colorimetric ATPase assay (lower left), and oligomycin-sensitive ATP synthesis using a
luciferase assay (lower right). Bar height corresponds to median value of individual measurements displayed as points (both technical and biological
replicates). Significance according to a t-test is represented as **Po0.01 or *Po0.05.
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Conclusions and outlook. Our study reveals mitochondrial
protein sorting as a promising new intervention point for the
treatment of ATP synthase disorders. This constitutes the first
demonstration that this fundamental process central to mito-
chondrial biogenesis and functionality can be fine-tuned via
pharmacological or genetic intervention to suppress disease-
associated phenotypes. While a more general inhibition of such a
major pathway would likely be detrimental, the slight modula-
tions applied here are beneficial in the context of mitochondrial
dysfunction, just as in a recent study that improved survival of a
mouse model of an ATP synthase disorder by inhibiting the
mTOR signalling pathway37. That we were led to this precise,
unexpected mode of action by a large-scale phenotypic screen and
a genome-wide mutant profile attests to the power of system
approaches for uncovering candidate intervention points. Our
findings indicate that the therapeutic benefits of modulating
protein sorting for ATP synthase deficiencies are conserved
between yeast and humans. Other studies have indicated that
moderately downregulating this pathway can help to maintain
mitochondrial proteostasis under stressful conditions33,34,38,
which along with future work may help to define how exactly
the modulations we describe here exert their therapeutic effects.
The numerous regulatory factors and mechanisms involved in
mitochondrial protein sorting now present new avenues to
explore therapeutic strategies for ATP synthase disorders. Due to
the fundamental role of this pathway, the therapeutic potential
of mitochondrial protein sorting could extend to a variety
of diseases involving mitochondrial dysfunction.
Methods
Data analysis. All statistical analyses in this study were performed using R;
the specific methods and packages are detailed in the appropriate sections.
Chemical screening assay. This assay was performed as previously described14:
240ml of exponentially growing fmc1D yeast, adjusted to an OD600 of 0.2, was
spread homogeneously using sterile glass beads (B3mm diameter) on a square
Petri dish (12 12 cm) containing rich solid yeast-peptone-glycerol (YPG)
medium (1% (w/v) BD Bacto yeast extract, 2% (w/v) BD Bacto peptone, 3% (v/v)
glycerol). Sterile filters were placed on the agar surface, and 2.5 ml of each
compound from the Prestwick chemical library dissolved in DMSO was applied to
the filters, with DMSO separately applied as a negative control. The plates were
incubated at 37 C for 6 days and scanned using a Snap Scan1212 (Agfa).
Yeast strain generation and in vivo assays. Growth assays with the yeast ATP
synthase disorder model strain fmc1D (MC6) on rich glycerol media with NaPT
(Fig. 1a) were carried out as previously described14. The strain background MC1
was used as wild type (MATa ade2–1 his3–11,15 trp1–1 leu2–3,112 ura3–1 (Di ER
OR); fmc1D/MC6 is the same genotype plus Dfmc1::HIS3)8. For Tim21
overexpression, we used the plasmid pYEP352-TIM21, a multicopy expression
vector with an insert of the TIM21 gene and its endogenous promoter and
terminator regions31. Strains overexpressing Tim21 (and control strains carrying
the empty vector pYEP352) were constructed by standard yeast plasmid
transformation39, except that the heat shock step was omitted due to the
thermosensitivity of the strains and instead, samples were left shaking gently
(200 r.p.m.) overnight at room temperature (22 C). Cells were plated on synthetic
glucose media lacking uracil for selection using the URA3 marker; the resulting
transformants were then restreaked to obtain single colonies. For growth tests
(Fig. 3c and Supplementary Fig. 4), strains were grown overnight at 30 C in
SD-Ura (1.7 g l 1 yeast nitrogen base without amino acids (BD Difco), 20 g l 1
glucose (Sigma), 1.92 g l 1 Yeast Synthetic Dropout Medium Supplement without
Uracil (Sigma)). The next day, cells were either: (a) directly transferred to rich
glycerol medium (YPG, 5 ml preculture in 100ml medium) in a 96-well plate
(NunclonD Surface) and grown at 36 C in a TECAN GENios multiwell plate
reader until saturation (48 h; liquid growth tests, Fig. 3c); or (b) diluted to
OD600B0.5 in SD-Ura and grown for 5 hours to reach exponential phase (spot
dilutions, Supplementary Fig. 4). The cultures were subsequently diluted to
OD600¼ 0.08 and then fivefold serially diluted in SGly-Ura (synthetic glycerol
media lacking uracil as above, but with 3% glycerol (v/v) instead of glucose). Five
microliters of each cell suspension were spotted on SGly-Ura agar plates that were
then incubated for 6–7 days at 35 C and scanned with a Canon CanoScan LiDE
600F. Growth rates (Fig. 3c) were estimated as the maximum slope of smooth fits
of the raw data (local polynomial fit of order 2, bandwidth of 3 h) using the
R/Bioconductor cellGrowth package.
Chemical–genomic profiling. The homozygous and heterozygous yeast deletion
pools were grown in YPDþ 25mM HEPES (pH adjusted to 6.8) supplemented with
1% DMSO (compound vehicle, negative control) or 8.35 mM of NaPT for 5 and 20
generations, respectively, as previously described21. Genomic DNA extraction, PCR
amplification of molecular tags and Genflex Tag16k array (Affymetrix)
hybridization, washing and scanning were performed as previously described21.
Analysis of chemical–genomic data. Each probe on the Genflex Tag16k array
(Affymetrix), known as the Tag4 array, is represented by five replicate features40.
Signal intensities were first log2-transformed. Next, each tag was summarized by
the median intensity across all (mostly five) matching probes on the array. We then
adjusted for overall signal intensity and PCR amplification of up and down tags as
follows: For each pool, some tags typically do not yield a signal above background
levels, either because the strain has vanished from the pool, it does not grow or it
has acquired too many mutations and therefore does not hybridize to the array.
Only tag intensities above 8 (a cutoff set from visual inspection of the intensity
distributions as separating a low- from a high-intensity subpopulation) were
considered above background. The intensity distributions of the up- and down-tag
populations in each microarray were shifted by a separate constant so that all
intensity distributions above background have equal medians. Differential strain
enrichment between DMSO and NaPT treatment was determined using limma’s
moderated t-test41 treating tag as an additive covariate to control for difference in
hybridization efficiency between up and down tags. P values were corrected for
multiple testing with the Benjamini–Hochberg method42, all using the R/
Bioconductor package limma. The fold changes calculated can be found in
Supplementary Data Set 2.
Comparison to previously generated deletion sensitivity profiles. The z-score
for every homozygous or heterozygous deletion strain was computed following the
same procedure as in Hillenmeyer et al.23, that is, z¼ (mctrl–mexp)/sctrl, where mctrl
and mexp are the means of the normalized log2 intensities in the DMSO controls
and the NaPT (8.35 mM) experiments, respectively, and sctrl is the sample standard
deviation of log2 intensities in the controls. The z-scores for the data from this
study can be found in Supplementary Data Set 2. These z-scores were then directly
compared with those for 726 experiments comprising 332 compounds from
profiles in ref. 23.
Isolation of mitochondria from Saccharomyces cerevisiae. Wild-type cells
(YPH499; MATa ura3-52 lys2-801_amber ade2-101_ochre trp1-D63 his3-D200
leu2-D1 (ref. 43)) were grown in liquid rich glycerol medium (YPG) at 30 C.
fmc1D and corresponding wild-type cells were precultured at 28 C in rich lactate
medium (1% (w/v) BD Bacto yeast extract, 1% (w/v) BD Bacto peptone, 2% (w/v)
Lactate, 1% (w/v) KH2PO4, 200mM adenine, adjusted to pH 5.5 with KOH) and
subsequently shifted to 37 for 20–24 h before harvesting. Cells transformed with
plasmid pYEP352-TIM21 or pYEP352 were precultured at 28 C in liquid synthetic
minimal medium (0.67% (w/v) yeast nitrogen base, 0.077% CSM amino acid mix
minus uracil, 3% (v/v) glycerol, 0.2% (w/v) glucose) to ensure maintenance of the
plasmids and then transferred to rich lactate medium at 37 C for 20–24 h. In vivo
NaPT treatment was performed using fmc1D and corresponding wild-type cells
carrying the empty vector pYEP352. After a 24-h preculture in liquid synthetic
minimal medium at 28 C, 120 nM NaPT was added and the preculture was
continued for another 24 h. Subsequently, cells were transferred to rich lactate
medium containing 120 nM NaPT and grown at 37 C for 20 h. Mitochondria were
isolated by differential centrifugation44. For the bioenergetic measurements
(respiration and ATP synthesis/hydrolysis assays) as well as for Supplementary
Fig. 5d–f, a slightly different isolation protocol was used45.
Import of precursor proteins into isolated mitochondria. For generation of
radiolabelled Qcr8 and Su h, linear DNA templates with SP6 promoters were
synthesized by PCR and transcribed in vitro using the mMESSAGE mMACHINE
SP6 kit (Invitrogen, USA). mRNA was purified (MEGAclear kit, Invitrogen) and
translated in reticulocyte lysate (Flexi Rabbit Reticulocyte Lysate System, Promega)
in the presence of [35S]methionine. [35S]cytochrome b2-DHFR, [35S]cytochrome
b2D-DHFR, [35S]Tom40 and [35S]AAC were synthesized by coupled in vitro
transcription/translation using plasmid templates and the TNT SP6 Quick coupled
kit (Promega) in the presence of [35S]methionine. [35S]cytochrome b2-DHFR is a
fusion protein consisting of the N-terminal 220 amino acids of the S. cerevisiae
cytochrome b2 precursor (including the mitochondrial import signals) fused to
mouse dihydrofolate reductase46. On translocation via the TIM23 complex, the
N-terminal presequence of this precursor is cleaved by the mitochondrial
processing peptidase (MPP), resulting in an intermediate (i) form. Downstream of
the N-terminal presequence, [35S]cytochrome b2-DHFR harbours a stop-transfer
signal that prevents complete translocation of the protein into the matrix and
promotes its integration into the inner mitochondrial membrane, followed by a
second processing by the inner membrane protease and release of a soluble mature
(m) form into the intermembrane space. [35S]cytochrome b2D-DHFR is similar to
[35S]cytochrome b2-DHFR but lacks the stop-transfer signal (amino acids 47–65)
and is therefore fully translocated across the inner membrane into the matrix and
accumulates as the intermediate (i) processing form47. Recombinantly expressed
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cytochrome b2D-DHFR carries the same deletion of the stop-transfer signal as
[35S]cytochrome b2D-DHFR but is based on a DHFR fusion of a shorter part of
cytochrome b2 (amino acids 1–167). The resulting cytochrome b2D-DHFR fusion
protein was expressed from the plasmid pUHE 73-1 in Escherichia coli strain BMH
71-18 and purified as previously described48. Protein import reactions typically
contained 50mg of isolated mitochondria (total protein amount) diluted in 100 ml
import buffer (250mM sucrose, 80mM KCl, 5mM MgCl2, 5mM methionine,
10mM KH2PO4, 10mM MOPS–KOH, pH 7.2, 3% (w/v) bovine serum albumin,
2mM NADH and 4mM ATP). No bovine serum albumin was included in import
reactions using recombinantly expressed b2D-DHFR. Reactions were supplemented
with an ATP-regenerating system (20mM creatine phosphate, 0.1mgml 1
creatine kinase) for the import and assembly of Qcr8, Su h, Tom40 and AAC.
Samples were prewarmed to 25 C, incubated with either CuCl2, NaPT or DMSO
for 5–15min where indicated, and import reactions were started by the addition of
precursor proteins. Import of Tom40 was stopped by transferring the reactions to
ice. Import reactions of all other precursors were terminated by the addition of
AVO mix (8 mM antimycin A, 1 mM valinomycin, 20mM oligomycin; final
concentrations)49. Where indicated, non-imported precursors were removed by
treatment with 50mgml 1 proteinase K (Roche). Mitochondria were washed with
SEM buffer (250mM sucrose, 10mMMOPS, pH 7.2, 1mM EDTA) and pelleted by
centrifugation. Pellets were either solubilised in Laemmli buffer for analysis by
SDS–PAGE or in digitonin buffer (20mM Tris-HCl, pH 7.4, 0.1mM EDTA, 10%
(v/v) glycerol, 50mM NaCl, 1% (w/v) digitonin, 1mM PMSF (Roth)) for analysis
by blue native electrophoresis (BN-PAGE). Radiolabelled proteins were detected by
digital autoradiography and quantified using the ImageQuant(TM) software (GE
Healthcare Life Sciences); quantifications for Fig. 2a,b can be found in
Supplementary Data Set 3. Import of the recombinantly expressed b2D-DHFR
(Fig. 2c) was assessed by western blotting using a polyclonal antibody directed
against the DHFR moiety of the preprotein.
Statistical analysis of import dynamics. For each substrate (Fig. 2a,b), three
independent import time series were obtained (Supplementary Data Set 3). Within
each series, the band intensities corresponding to the imported, protease-resistant
proteins were normalized by dividing by the intensity for DMSO at the final time
point. Next, a linear model with intercept 0 was fitted by least square regression in
the presence or absence of NaPT, separately. The ratio of the fitted slopes repre-
sents how the rate of import was affected by the presence of NaPT. To assess
statistical significance, the asymptotic likelihood ratio test was applied, comparing
the goodness of fit of this model with two slopes against a null model assuming a
common slope to both conditions (presence or absence of NaPT).
BN-PAGE of isolated mitochondria. For BN-PAGE analysis50, mitochondrial
extracts (starting from 40–100mg mitochondrial proteins) solubilized with digitonin
(digitonin to protein ratio of 10 g/g) were separated on NativePAGE 3–12% Bis-Tris
gels (Invitrogen, USA) or on homemade blue native gradient gels (5–10%, 4–16.5%
or 6–16.5% polyacrylamide). After electrophoresis, gels were either stained with
Coomassie blue, incubated in a solution of 5mM ATP, 5mM MgCl2, 0.05% lead
acetate, 50mM glycine–NaOH, pH 8.4 to detect ATPase activity51, or transferred to
nitrocellulose or PVDF membranes and analysed by western blotting52. Membranes
were first incubated with peptide antibodies against Cox4, Atp4 or F1b, or
polyclonal antibodies raised against cytochrome b. Subsequently, they were
incubated with peroxidase-conjugated secondary antibodies at a 1:5,000 dilution
(Promega or Sigma) and revealed using enhanced chemiluminescence.
Membrane potential measurement. Mitochondria isolated from wild-type
(YPH499) yeast or fmc1D and the corresponding wild type carrying Tim21 over-
expression or empty plasmids were diluted in membrane potential assay buffer
(0.6M sorbitol, 0.1% (w/v) bovine serum albumin, 10mM MgCl2, 0.5mM EDTA,
20mM KPi pH 7.2; supplemented with 5mM succinate and 5mM malate for
fmc1D and corresponding wild type) with or without 150 mM NaPT. The mito-
chondrial inner membrane potential was determined by measuring fluorescence
quenching of the membrane potential-sensitive dye 3,30-dipropylthiadicarbocya-
nine iodide [DiSC3(5)] using an Aminco-Bowman series 2 luminescence spectro-
meter (Thermo Spectronic) at room temperature with an excitation of 622 nm and
an emission of 670 nm (ref. 53).
Respiration rates. For whole-cell respiratory activity measurements, cells were
resuspended in YP medium at 1 OD600 nmml 1 and oxygen consumption rates
were measured with a Clark electrode. The reactions were started by adding 1%
pure ethanol as the substrate. Uncoupled maximal respiratory rates were measured
after adding 80 mM carbonyl cyanide 3-chlorophenylhydrazone (CCCP). For
respiration measurements in isolated mitochondria, oxygen consumption rates
were measured with a Clark electrode in the respiration buffer (0.65M mannitol,
0.36mM EGTA, 5mM Tris-phosphate, 10mM Tris-maleate, pH 6.8) as previously
described54: mitochondria (0.15mgml 1) were placed in a 1.2-ml thermostatically
controlled chamber at 28 C in respiration buffer. Uncoupled maximal respiratory
rates were measured in the presence of 4mM NADH as substrate and 4 mM CCCP
as uncoupler. The specific activity of cytochrome c oxidase was measured using a
combination of 12.5mM ascorbate and 1.4mM N,N,N’,N’-Tetramethyl-p-
phenylenediamine dihydrochloride (TMPD) to reduce cytochrome c and in the
presence of 4 mM CCCP as uncoupler. All of these measurements can be found in
Supplementary Data Set 4.
ATP synthesis and hydrolysis. For ATP synthesis rate measurements, mito-
chondria were incubated as for oxygen consumption experiments. The reaction was
started by the addition of 4mM NADH and 1mM ADP and stopped by addition of
3.5% perchloric acid and 12.5mM EDTA. The samples were then neutralized to pH
6.5 by the addition of KOH and 0.3M MOPS. ATP was quantified in a luciferin/
luciferase assay (Perkin Elmer) with an LKB bioluminometer. ATP hydrolysis rates
were measured at pH 8.4 with a previously described procedure55. Oligomycin-
sensitive ATP synthesis and hydrolysis rates were measured by adding oligomycin
(20 mgmg 1 of protein) to estimate the relative amounts of fully assembled F1F0-
ATP synthase. These measurements can be found in Supplementary Data Set 4.
Statistical analysis of bioenergetics data. For measurements of respiration rates
(whole-cell and isolated mitochondria), specific cytochrome c oxidase activity, and
ATP synthesis and hydrolysis, statistical significance of the differences between
strains carrying the Tim21 overexpression versus empty plasmid was assessed using
a one-sided t-test assuming equal variance in both the groups. Two biological
replicates were measured per strain. Technical replicates, which displayed lower
variance than biological replicates, were summarized by their median value before
testing. The individual measurements can be found in Supplementary Data Set 4.
Human cell lines and culture conditions. The cybrid survival assays with NaPT
treatment in Fig. 1b and Supplementary Fig. 1e were performed as previously
described14: cell lines were first cultivated in high-glucose DMEM, after which the
medium was removed and survival measurements were carried out in glucose-
deprived DMEM supplemented with the indicated concentrations of NaPT,
dihydrolipoic acid (DHLA;þ control)18 or DMSO ( control); no antibiotics were
used. Survival assays started with 3.5 104 JCP239 eb13.13 (NARP atp6-T8993G)
cells18 and 2 104 JCP213 (control) cells being plated in 12-well plates containing
DMEM with high glucose (4.5 g l 1) for 24 h. For each treatment condition, three
wells were used. NaPT solutions in DMSO were diluted 1:1,000 in the medium.
DHLA at 100mM or the same volume of DMSO were used as positive and negative
controls, respectively. After 6 days of incubation with the drugs, cell proliferation
was estimated by cell counting using the Scepter (Millipore). Experiments were
performed at least three times per condition and the values obtained can be found
in Supplementary Data Set 1. Cell counts in each condition were expressed as a
proportion of cell counts in DMSO control experiments (‘Percentage of live cells
(relative to untreated)’). For statistical analysis, an analysis of variance model was
fitted with intercept at 100% growth, and significance of the effect for each
concentration was assessed by the t-test using the R package lmtest. TIMM21
overexpression experiments were performed using JCP239 eb13.13 and JCP213
cybrid cell lines transduced with lentiviral constructs overexpressing TIMM21
(pLOC-Tim21 OHS5897-101185497) or RFP as control (pLOC-RFP-control
OHS5832), both provided by Open Biosystems. HIV1-based lentiviruses were
produced in HEK293FT cells according to ref. 56. Both cell lines were transduced
with a multiplicity of infection of 1. At 4 days post transduction, cells carrying the
different constructs were seeded separately in six-well plates (105 cells per well)
containing DMEM with glucose. After 24 h of growth, three wells for each line were
used to estimate the total number of cells per well using a C6 flow cytometer
(Accuri). The medium was removed from remaining wells and cells were further
incubated with DMEM without glucose (as described above). After 6 days of
incubation, cell proliferation/survival was estimated by cell counting using a C6
flow cytometer (Accuri). Experiments were performed at least three times per
condition and three different wells were counted for each line in each experiment;
the values obtained can be found in Supplementary Data Set 1. Cell counts in each
condition were expressed as a proportion of the cell counts following the first 24 h
of growth in Fig. 3d. To confirm TIMM21 overexpression, 10 mg protein of cell
lysates from JCP239 cells transduced with overexpression constructs were
separated on SDS–PAGE and subjected to western blot analysis using anti-
TIMM21 (anti-C18orf55) affinity-purified rabbit polyclonal antibodies
(Proteintech Europe) and revealed by enhanced chemiluminescence.
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